A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies

Arterial thrombosis plays a key role in cardiovascular diseases. Hence, developing more effective antithrombotic agents is necessary. We designed a ruthenium (II)-derived complex, [Ru(η(6)-cymene)2-(1H-benzoimidazol-2-yl)-quinoline Cl]BF(4) (TQ-6), as a new antiplatelet drug. TQ-6 (0.3 µM) exhibited...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsia, Chih-Hsuan, Velusamy, Marappan, Sheu, Joen-Rong, Khamrang, Themmila, Jayakumar, Thanasekaran, Lu, Wan-Jung, Lin, Kuan-Hung, Chang, Chao-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573325/
https://www.ncbi.nlm.nih.gov/pubmed/28842683
http://dx.doi.org/10.1038/s41598-017-09695-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573325/
https://www.ncbi.nlm.nih.gov/pubmed/28842683
http://dx.doi.org/10.1038/s41598-017-09695-z

Ejemplares similares